X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3007) 3007
Publication (188) 188
Book Review (52) 52
Book Chapter (49) 49
Book / eBook (6) 6
Conference Proceeding (6) 6
Dissertation (1) 1
Magazine Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1950) 1950
cardiac & cardiovascular systems (1666) 1666
antiarrhythmic drugs (1302) 1302
atrial fibrillation (1072) 1072
male (1048) 1048
index medicus (1005) 1005
female (989) 989
anti-arrhythmia agents - therapeutic use (897) 897
middle aged (766) 766
aged (689) 689
catheter ablation (558) 558
antiarrhythmic-drug therapy (556) 556
treatment outcome (555) 555
animals (535) 535
atrial fibrillation - drug therapy (467) 467
electrocardiography (456) 456
pharmacology & pharmacy (445) 445
amiodarone (444) 444
atrial fibrillation - physiopathology (385) 385
antiarrhythmic-drugs (359) 359
sinus rhythm (340) 340
adult (339) 339
anti-arrhythmia agents - pharmacology (338) 338
arrhythmias (317) 317
risk factors (308) 308
mortality (296) 296
defibrillators, implantable (293) 293
therapy (287) 287
arrhythmia (285) 285
efficacy (280) 280
antiarrhythmic drug (279) 279
atrial fibrillation - therapy (272) 272
anti-arrhythmia drugs (271) 271
implantable cardioverter-defibrillator (271) 271
sudden cardiac death (271) 271
myocardial-infarction (270) 270
anti-arrhythmia agents - adverse effects (261) 261
ablation (253) 253
tachycardia (253) 253
management (247) 247
electrophysiology (242) 242
cardiovascular (240) 240
cardiac arrhythmia (235) 235
anti-arrhythmia agents - administration & dosage (230) 230
randomized-trial (227) 227
time factors (227) 227
arrhythmias, cardiac - drug therapy (220) 220
follow-up studies (213) 213
heart (211) 211
cardiology (209) 209
prevention (209) 209
recurrence (209) 209
fibrillation (207) 207
radiofrequency ablation (204) 204
follow-up (199) 199
ventricular tachycardia (199) 199
analysis (197) 197
medicine, general & internal (196) 196
heart-failure (195) 195
atrial fibrillation - surgery (193) 193
care and treatment (190) 190
heart failure (189) 189
risk (189) 189
death, sudden, cardiac - prevention & control (179) 179
radiofrequency catheter ablation (178) 178
dogs (177) 177
heart rate - drug effects (177) 177
acute myocardial-infarction (173) 173
engineering, biomedical (169) 169
flecainide (168) 168
cardioversion (167) 167
retrospective studies (167) 167
aged, 80 and over (166) 166
amiodarone - therapeutic use (166) 166
medicine & public health (161) 161
atrial fibrillation - diagnosis (159) 159
drug therapy (159) 159
electric countershock (159) 159
ventricular arrhythmias (157) 157
atrial-fibrillation (154) 154
catheter ablation - methods (153) 153
prospective studies (149) 149
heart conduction system - drug effects (148) 148
rhythm control (148) 148
ventricular fibrillation (146) 146
prognosis (143) 143
dose-response relationship, drug (141) 141
quality-of-life (141) 141
pulmonary vein isolation (140) 140
trial (140) 140
action potentials - drug effects (138) 138
peripheral vascular disease (136) 136
defibrillators (135) 135
congestive-heart-failure (134) 134
abridged index medicus (131) 131
tachycardia, ventricular - therapy (131) 131
arrhythmias, cardiac - physiopathology (130) 130
risk assessment (126) 126
flutter (124) 124
implants, artificial (124) 124
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2846) 2846
German (128) 128
Russian (26) 26
French (23) 23
Spanish (14) 14
Japanese (9) 9
Polish (5) 5
Portuguese (5) 5
Hungarian (3) 3
Croatian (1) 1
Czech (1) 1
Georgian (1) 1
Italian (1) 1
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e531S - e575S
Background: The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is... 
DIRECT-CURRENT CARDIOVERSION | STROKE PREVENTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | ORAL ANTICOAGULANT-THERAPY | RISK STRATIFICATION SCHEMES | MAJOR VASCULAR EVENTS | PULMONARY-VEIN ABLATION | ACUTE CORONARY SYNDROME | ECHOCARDIOGRAPHY-GUIDED CARDIOVERSION | ANTIARRHYTHMIC-DRUG THERAPY | CRITICAL CARE MEDICINE | Ticlopidine - therapeutic use | Humans | Electric Countershock | Hemorrhage - prevention & control | Dabigatran | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Stroke - prevention & control | beta-Alanine - adverse effects | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Atrial Fibrillation - blood | International Normalized Ratio | Stroke - blood | Atrial Flutter - complications | Atrial Flutter - drug therapy | Hemorrhage - chemically induced | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 17, pp. 1587 - 1595
In this trial, patients with symptomatic paroxysmal atrial fibrillation were assigned to either radiofrequency ablation or antiarrhythmic drug therapy as... 
TRIAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | EFFICACY | SUBSTRATE | PULMONARY VEIN ABLATION | GUIDELINES | CATHETER ABLATION | COMPLICATIONS | SOCIETY | ANTIARRHYTHMIC-DRUG THERAPY | Follow-Up Studies | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Propafenone - adverse effects | Cost of Illness | Male | Treatment Outcome | Anti-Arrhythmia Agents - therapeutic use | Atrial Fibrillation - surgery | Flecainide - adverse effects | Anti-Arrhythmia Agents - adverse effects | Atrial Flutter - diagnosis | Intention to Treat Analysis | Statistics, Nonparametric | Quality of Life | Female | Aged | Propafenone - therapeutic use | Catheter Ablation - adverse effects | Atrial Fibrillation - diagnosis | Electrocardiography, Ambulatory | Flecainide - therapeutic use | Care and treatment | Usage | Atrial fibrillation | Patient outcomes | Anti-arrhythmia drugs | Radiofrequency ablation | Dosage and administration | Drug therapy | Heart | Fees & charges | Cardiac arrhythmia | Stroke | Arrhythmia | Platelet-activating factor | Cardiovascular disease | Grants | Patients | Catheters | Manuscripts | Tamponade | Fibrillation | Motivation | Electrocardiography | Drug dosages | Antiarrhythmic agents | Veins & arteries | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Journal Article
Pharmacological Research, ISSN 1043-6618, 06/2019, Volume 144, pp. 257 - 263
Journal Article
Circulation, ISSN 0009-7322, 07/2014, Volume 130, Issue 1, pp. 94 - 125
Heart failure | Implantable cardioverter- defibrillator therapy | Sudden cardiac death | AHA Scientific Statements | heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | IDIOPATHIC DILATED CARDIOMYOPATHY | LONG-TERM SURVIVAL | sudden cardiac death | ANTIARRHYTHMIC-DRUG THERAPY | CARDIOVASCULAR-DATA-REGISTRY | ASSIST DEVICE IMPLANTATION | LEFT-VENTRICULAR DYSFUNCTION | implantable cardioverter-defibrillator therapy | ACUTE MYOCARDIAL-INFARCTION | ASSOCIATION TASK-FORCE | PERIPHERAL VASCULAR DISEASE | CORONARY-ARTERY-DISEASE | Humans | Death, Sudden, Cardiac - prevention & control | Risk | Death, Sudden, Cardiac - etiology | Equipment Design | Patient Selection | Heart Failure - therapy | Myocardial Infarction - therapy | Multicenter Studies as Topic | Time Factors | Defibrillators, Implantable | Ventricular Fibrillation - complications | Troponin - blood | Tachycardia, Ventricular - therapy | Ventricular Fibrillation - prevention & control | Tachycardia, Ventricular - complications | Postoperative Period | Treatment Outcome | Tachycardia, Ventricular - prevention & control | Cardiomyopathies - therapy | Myocardial Revascularization | Randomized Controlled Trials as Topic | Cardiopulmonary Resuscitation | Electric Countershock - instrumentation | Syncope - etiology | Biomarkers | Ventricular Fibrillation - therapy | Equipment Failure | Heart Arrest - therapy | Usage | Care and treatment | Conferences, meetings and seminars | Medical societies | Implantable cardioverter-defibrillators | Health aspects | Heart diseases | Standards
Journal Article
Europace, ISSN 1099-5129, 10/2010, Volume 12, Issue 10, pp. 1360 - 1420
Rhythm control | CARDIAC & CARDIOVASCULAR SYSTEMS | Atrial fibrillation | LONG-TERM SURVIVAL | Anticoagulation | II RECEPTOR BLOCKADE | Upstream therapy | RADIOFREQUENCY CATHETER ABLATION | ANGIOTENSIN-CONVERTING ENZYME | Guidelines | Rate control | ANTIARRHYTHMIC-DRUG THERAPY | PARKINSON-WHITE-SYNDROME | European Society of Cardiology | Left atrial ablation | CARDIAC RESYNCHRONIZATION THERAPY | PULMONARY-VEIN ISOLATION | POLYUNSATURATED FATTY-ACIDS | CONGESTIVE-HEART-FAILURE | Pulmonary vein isolation | Prevalence | Humans | Middle Aged | Wolff-Parkinson-White Syndrome - epidemiology | Male | Atrial Fibrillation - physiopathology | Heart Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Heart Valve Diseases - epidemiology | Fibrinolytic Agents - therapeutic use | Heart Rate - physiology | Female | Hyperthyroidism - epidemiology | Atrial Fibrillation - diagnosis | Platelet Aggregation Inhibitors - therapeutic use | Heart Failure - epidemiology | Electric Countershock - methods | Acute Coronary Syndrome - epidemiology | Athletes - statistics & numerical data | Comorbidity | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anti-Arrhythmia Agents - therapeutic use | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Pregnancy | Atrial Fibrillation - epidemiology | Electric Countershock - instrumentation | Diabetes Mellitus - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Atrial Fibrillation - etiology | Acute Coronary Syndrome - therapy | Heart Valve Diseases - therapy | Aged | Cardiomyopathy, Hypertrophic - epidemiology | Lung Diseases - epidemiology | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Circulation: Arrhythmia and Electrophysiology, ISSN 1941-3149, 09/2019, Volume 12, Issue 9, pp. e007414 - e007414
BACKGROUND:Despite the publication of several randomized clinical trials comparing catheter ablation (CA) with medical therapy (MT) in patients with atrial... 
1ST-LINE TREATMENT | MULTICENTER | CARDIAC & CARDIOVASCULAR SYSTEMS | RHYTHM CONTROL | meta-analysis | RISK | catheter ablation | PULMONARY-VEIN ABLATION | randomized controlled trial | ANTIARRHYTHMIC-DRUG THERAPY | atrial fibrillation | QUALITY-OF-LIFE | SYSTOLIC DYSFUNCTION | CONGESTIVE-HEART-FAILURE | humans | RADIOFREQUENCY ABLATION
Journal Article
Journal Article